Latest publications Tumour Marker Group

Gehin JE, Klaasen RA, Norli ES, Warren DJ, Syversen SW, Goll GL, Bjøro T, Kvien TK, Mjaavatten MD, Bolstad N (2021)
Rheumatoid factor and falsely elevated results in commercial immunoassays: data from an early arthritis cohort
Rheumatol Int (in press)
DOI 10.1007/s00296-021-04865-9, PubMed 33944985

Syversen SW, Goll GL, Jørgensen KK, Sandanger Ø, Sexton J, Olsen IC, Gehin JE, Warren DJ, Brun MK, Klaasen RA, Karlsen LN, Noraberg G, Zettel C, Ljoså MKA, Haugen AJ, Njålla RJ, Bruun TJ, Seeberg KA, Michelsen B, Strand EK, Skorpe S, Blomgren IM, Bragnes YH, Dotterud CK, Thune T et al. (2021)
Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial
JAMA, 325 (17), 1744-1754
DOI 10.1001/jama.2021.4172, PubMed 33944876

Köksal H, Baken E, Warren DJ, Løset GÅ, Inderberg EM, Wälchli S (2019)
Chimeric antigen receptor preparation from hybridoma to T-cell expression
Antib Ther, 2 (2), 56-63
DOI 10.1093/abt/tbz007, PubMed 33928223